CN116472068A - 治疗性放射性标记的缀合物及其在疗法中的用途 - Google Patents

治疗性放射性标记的缀合物及其在疗法中的用途 Download PDF

Info

Publication number
CN116472068A
CN116472068A CN202180075143.7A CN202180075143A CN116472068A CN 116472068 A CN116472068 A CN 116472068A CN 202180075143 A CN202180075143 A CN 202180075143A CN 116472068 A CN116472068 A CN 116472068A
Authority
CN
China
Prior art keywords
compound
gsao
therapeutic
formula
radioisotope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180075143.7A
Other languages
English (en)
Chinese (zh)
Inventor
菲利普·霍格
伊凡·霍肖恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Century Research Institute Of Cancer Medicine And Cell Biology
The University of Sydney
Original Assignee
Century Research Institute Of Cancer Medicine And Cell Biology
The University of Sydney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020903727A external-priority patent/AU2020903727A0/en
Application filed by Century Research Institute Of Cancer Medicine And Cell Biology, The University of Sydney filed Critical Century Research Institute Of Cancer Medicine And Cell Biology
Publication of CN116472068A publication Critical patent/CN116472068A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1001—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy using radiation sources introduced into or applied onto the body; brachytherapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
    • C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202180075143.7A 2020-10-14 2021-10-14 治疗性放射性标记的缀合物及其在疗法中的用途 Pending CN116472068A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020903727 2020-10-14
AU2020903727A AU2020903727A0 (en) 2020-10-14 Conjugates and their use in therapy
PCT/AU2021/051203 WO2022077068A1 (en) 2020-10-14 2021-10-14 Therapeutic radiolabelled conjugates and their use in therapy

Publications (1)

Publication Number Publication Date
CN116472068A true CN116472068A (zh) 2023-07-21

Family

ID=81207378

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180075143.7A Pending CN116472068A (zh) 2020-10-14 2021-10-14 治疗性放射性标记的缀合物及其在疗法中的用途

Country Status (10)

Country Link
US (1) US20230398240A1 (cg-RX-API-DMAC7.html)
EP (1) EP4228710A4 (cg-RX-API-DMAC7.html)
JP (1) JP7890301B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230130610A (cg-RX-API-DMAC7.html)
CN (1) CN116472068A (cg-RX-API-DMAC7.html)
AU (1) AU2021359638A1 (cg-RX-API-DMAC7.html)
CA (1) CA3195410A1 (cg-RX-API-DMAC7.html)
IL (1) IL302033A (cg-RX-API-DMAC7.html)
MX (1) MX2023004327A (cg-RX-API-DMAC7.html)
WO (1) WO2022077068A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220152229A1 (en) 2019-04-12 2022-05-19 Centenary Institute Of Cancer Medicine And Cell Biology Conjugates and their use as imaging agents
US20250269072A1 (en) * 2021-10-14 2025-08-28 Centenary Institute Of Cancer Medicine And Cell Biology Processes for preparing radiolabelled conjugates

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
CN108135964A (zh) * 2015-06-19 2018-06-08 分子防御公司 谷胱甘肽制剂和使用方法
CN114206844A (zh) * 2019-04-12 2022-03-18 癌症医学和细胞生物学百年研究所 缀合物及其作为成像剂的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3275883T (lt) 2015-03-25 2021-08-25 Fujifilm Corporation Naujo azotą turinčio junginio arba jo druskos gamybos būdas ir jo tarpinio junginio gamyba

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1822861A (zh) * 2003-07-24 2006-08-23 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US20070269375A1 (en) * 2003-07-24 2007-11-22 Bracco Imaging S.P.A. Stable Radiopharmaceutical Compositions and Methods for Preparation
WO2016088116A1 (en) * 2014-12-05 2016-06-09 University Health Network Use of antioxidants as radio-protective agents
CN108135964A (zh) * 2015-06-19 2018-06-08 分子防御公司 谷胱甘肽制剂和使用方法
CN114206844A (zh) * 2019-04-12 2022-03-18 癌症医学和细胞生物学百年研究所 缀合物及其作为成像剂的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
IVAN HO SHON ET AL: "Preparation of a Dithiol-Reactive Probe for PET Imaging of Cell Death", 《FUNCTIONAL DISULPHIDE BONDS》, vol. 1967, 9 May 2019 (2019-05-09), pages 296 *

Also Published As

Publication number Publication date
JP7890301B2 (ja) 2026-07-14
IL302033A (en) 2023-06-01
KR20230130610A (ko) 2023-09-12
US20230398240A1 (en) 2023-12-14
MX2023004327A (es) 2023-08-30
CA3195410A1 (en) 2022-04-21
EP4228710A4 (en) 2025-04-09
EP4228710A1 (en) 2023-08-23
WO2022077068A1 (en) 2022-04-21
JP2023547954A (ja) 2023-11-14
AU2021359638A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
EP3498308B1 (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
ES2736134T3 (es) Derivado peptídico de tiourea, compuesto marcado con radioisótopos que contiene el mismo y composición farmacéutica que contiene el mismo como ingrediente activo para tratar o diagnosticar el cáncer de próstata
AU2009200201B2 (en) Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20120065365A1 (en) Stable Radiopharmaceutical Compositions and Methods for Their Preparation
ES2794581T3 (es) Procedimientos y kits para preparar complejos de radionúclidos
US12296030B2 (en) Conjugates and their use as imaging agents
CN116217505B (zh) 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂
JP2024532521A (ja) ペプチド-尿素誘導体、それを含む医薬組成物、及びそれらの使用
US20230398240A1 (en) Therapeutic radiolabelled conjugates and their use in therapy
JP2014500262A (ja) 放射線治療のための177ルテチウム標識されたボンベシン類似体
JP2022549258A (ja) セラノスティックスとして使用するための放射性標識grprアンタゴニスト
US20250269072A1 (en) Processes for preparing radiolabelled conjugates
CN119874628B (zh) 一种含氮化合物及其制备方法与用途
EP4735056A1 (en) Methods for the diagnosis and/or treatment of neuroendocrine cancers
HK40008701B (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide
HK40008701A (en) Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination